Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLK2 | Q86UE8 | 14/20 | 1.00 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 1.00 |
| ▸ | NEK7 | Q8TDX7 | 1/20 | 1.00 |
| ▸ | NEK6 | Q9HC98 | 1/20 | 1.00 |
| ▸ | MELK | Q14680 | 2/20 | 0.69 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.51 |
| ▸ | CDK1 | P06493 | 2/20 | 0.47 |
| ▸ | RET | P07949 | 2/20 | 0.47 |
| ▸ | CDK2 | P24941 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | KDR | P35968 | 2/20 | 0.47 |
| ▸ | GSK3A | P49840 | 2/20 | 0.47 |
| ▸ | GSK3B | P49841 | 2/20 | 0.47 |
| ▸ | CDK7 | P50613 | 2/20 | 0.47 |
| ▸ | CDK9 | P50750 | 2/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29908697 | 1.00 | TLK2 (1.00) | TLK2MAP3K11NEK7NEK6MELK | |
| SCHEMBL2230665 | 1.00 | TLK2 (1.00) | TLK2MAP3K11NEK7NEK6MELK | |
| SCHEMBL1395126 | 1.00 | TLK2 (1.00) | TLK2MAP3K11NEK7NEK6MELK | |
| SCHEMBL16231615 | 0.82 | TLK2 (0.70) | TLK2MAP3K11NEK7NEK6MELK | |
| SCHEMBL23252181 | 0.81 | MELK (1.00) | TLK2MAP3K11NEK7NEK6MELK | |
| SCHEMBL16234131 | 0.81 | TLK2 (0.69) | TLK2MAP3K11NEK7NEK6MELK | |
| SCHEMBL16234132 | 0.81 | MAP3K11 (0.68) | TLK2MAP3K11NEK7NEK6MELK | |
| SCHEMBL16234139 | 0.79 | TLK2 (0.65) | TLK2MAP3K11NEK7NEK6MELK | |
| SCHEMBL16234143 | 0.78 | TLK2 (0.64) | TLK2MAP3K11NEK7NEK6MELK | |
| SCHEMBL9886520 | 0.78 | MAP3K11 (0.64) | TLK2MAP3K11NEK7NEK6MELK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230053473-A1 | ENHANCING EXPRESSION OF LINE-1 ENCODED ORF2P FOR CANCER THERAPEUTICS | UNIV JOHNS HOPKINS (US) | 2023-02-23 | — | — | US | claimed |
| WO-2021134040-A2 | ENHANCING EXPRESSION OF LINE-1 ENCODED ORF2P FOR CANCER THERAPEUTICS | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-07-01 | — | — | WO | claimed |
| EP-3282015-B1 | METHOD FOR CELLULAR RNA EXPRESSION | BIONTECH RNA PHARMACEUTICALS GMBH (DE) | 2020-05-20 | — | — | EP | claimed |
| EP-3282015-A2 | METHOD FOR CELLULAR RNA EXPRESSION | BioNTech RNA Pharmaceuticals GmbH (DE) | 2018-02-14 | — | — | EP | claimed |
| US-20180000794-A1 | COMPOSITION FOR PREVENTION OR TREATMENT OF BRONCHIAL ASTHMA COMPRISING PKR INHIBITOR AS ACTIVE INGREDIENT | INDUSTRIAL COOPERATION FOUNDATION CHONBUK NATIONAL UNIVERSITY (KR) | 2018-01-04 | — | — | US | claimed |
| EP-2646557-B1 | METHOD FOR CELLULAR RNA EXPRESSION | BIONTECH RNA PHARMACEUTICALS GMBH (DE) | 2017-08-09 | — | — | EP | claimed |
| US-20150314018-A1 | METHOD FOR CELLULAR RNA EXPRESSION | BioNTech SE (DE) | 2015-11-05 | — | — | US | claimed |
| EP-2917350-A1 | METHOD FOR CELLULAR RNA EXPRESSION | BioNTech AG (DE) | 2015-09-16 | — | — | EP | claimed |
| WO-2014071963-A1 | METHOD FOR CELLULAR RNA EXPRESSION | BIONTECH AG (DE) | 2014-05-15 | — | — | WO | claimed |
| WO-2014072061-A1 | METHOD FOR CELLULAR RNA EXPRESSION | BIONTECH AG (DE) | 2014-05-15 | — | — | WO | claimed |
| US-20140030808-A1 | Method for Cellular RNA Expression | BIONTECH AG (DE) | 2014-01-30 | — | — | US | claimed |
| EP-2646557-A1 | METHOD FOR CELLULAR RNA EXPRESSION | Biontech AG (DE) | 2013-10-09 | — | — | EP | claimed |
| WO-2012072269-A1 | METHOD FOR CELLULAR RNA EXPRESSION | BIONTECH AG (DE) | 2012-06-07 | — | — | WO | claimed |
| WO-2012072096-A1 | METHOD FOR CELLULAR RNA EXPRESSION | BIONTECH AG (DE) | 2012-06-07 | — | — | WO | claimed |
| EP-4368702-A2 | METHOD OF ENHANCING RNA EXPRESSION IN A CELL | BioNTech SE (DE) | 2024-05-15 | — | — | EP | disclosed |
| EP-3681901-B1 | METHOD OF ENHANCING RNA EXPRESSION IN A CELL | BioNTech SE (DE) | 2024-03-27 | — | — | EP | disclosed |
| WO-2023208028-A1 | CIRCULAR RNA WITH 16 BP-26 BP DOUBLE-STRANDED STEM-LOOP STRUCTURE FOR TREATING PSORIASIS OR ALZHEIMER'S DISEASE | 中国科学院分子细胞科学卓越创新中心 | 2023-11-02 | — | — | WO | disclosed |
| WO-2012072269-A1 | METHOD FOR CELLULAR RNA EXPRESSION | BIONTECH AG (DE) | 2012-06-07 | — | — | WO | disclosed |
| US-20120010178-A1 | METHODS AND COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-01-12 | — | — | US | disclosed |
| WO-2010048273-A2 | METHODS AND COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180000794-A1 | COMPOSITION FOR PREVENTION OR TREATMENT OF BRONCHIAL ASTHMA COMPRISING PKR INHIBITOR AS ACTIVE INGREDIENT | PRKCA, PRKCH, PRKCB | TLK2 896/4885MAP3K11 109/4885NEK7 751/4885 |
| US-20150314018-A1 | METHOD FOR CELLULAR RNA EXPRESSION | EIF2AK2, IFNAR1, STAT1 | TLK2 3145/4885MAP3K11 3859/4885NEK7 1150/4885 |
| US-20120010178-A1 | METHODS AND COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SMN1; SMN2, CLN6, SNCA | TLK2 3429/4885MAP3K11 2921/4885NEK7 1788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.